PROMIMIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.8 SEK | +3.88% |
|
+1.13% | -18.04% |
| Feb. 28 | Promimic AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 28 | Promimic AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 17.07M 1.6M | Sales 2023 | 39.21M 3.66M | Capitalization | 602M 56.3M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -1.4M | Net income 2023 | -9M -841K | EV / Sales 2022 | 9.07 x |
| Net cash position 2022 | 58.8M 5.5M | Net cash position 2023 | 50.32M 4.7M | EV / Sales 2023 | 14.1 x |
| P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-65.5
x | Employees | 17 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 17.49% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.88% | ||
| 1 week | +1.13% | ||
| Current month | -1.47% | ||
| 1 month | -7.59% | ||
| 3 months | -21.87% | ||
| 6 months | -23.65% | ||
| Current year | -18.04% |
1 week
25.00
26.90
1 month
24.7031.00
Current year
24.7037.60
1 year
19.9538.00
3 years
8.4638.00
5 years
8.4638.00
10 years
8.4638.00
| Managers | Title | Age | Since |
|---|---|---|---|
Magnus Larsson
CEO | Chief Executive Officer | - | 17-01-17 |
| Founder | 52 | 03-12-31 | |
| Founder | 50 | 03-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sven Krook
BRD | Director/Board Member | 58 | 16-10-26 |
Tommy Karlsson
BRD | Director/Board Member | 78 | 17-12-31 |
| Founder | 52 | 03-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 26.8 | +3.88% | 5 779 |
| 24-05-20 | 25.8 | -0.77% | 7,143 |
| 24-05-17 | 26 | +0.78% | 4,875 |
| 24-05-16 | 25.8 | -1.90% | 3,370 |
| 24-05-15 | 26.3 | -0.75% | 1,153 |
Delayed Quote Nasdaq Stockholm, May 21, 2024 at 11:21 am EDT
More quotes
Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.04% | 45.01M | |
| +41.25% | 54.04B | |
| +43.57% | 41.96B | |
| -1.19% | 41.92B | |
| -7.59% | 28.35B | |
| +12.17% | 26.35B | |
| -22.42% | 19B | |
| +7.81% | 13B | |
| +29.08% | 12.28B | |
| +25.14% | 12.19B |
- Stock Market
- Equities
- PRO Stock
